Granisetron 1 mg Tablets, Non-fasting

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT00834522
First received: January 30, 2009
Last updated: September 1, 2009
Last verified: September 2009

January 30, 2009
September 1, 2009
July 2005
July 2005   (final data collection date for primary outcome measure)
  • Cmax (Maximum Observed Concentration) [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
Bioequivalence based on Cmax and AUC [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00834522 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Granisetron 1 mg Tablets, Non-fasting
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fed Conditions

The objective of this study is to evaluate the comparative bioavailability between granisetron hydrochloride 1 mg tablets (Teva Pharmaceuticals USA) and Kytril® 1 mg tablets (Roche, USA), after a single-dose in health subjects under fed conditions.

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Granisetron hydrochloride 1 mg tablets
    2 x 1 mg, single dose non-fasting
  • Drug: Kytril® 1 mg tablets
    2 x 1 mg, single dose non-fasting
  • Experimental: Granisetron
    Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
    Intervention: Drug: Granisetron hydrochloride 1 mg tablets
  • Active Comparator: Kytril®
    Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
    Intervention: Drug: Kytril® 1 mg tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
July 2005
July 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy, non-smoking, male and female subjects, 18 years of age or older.
  • BMI ≥ 19 and ≤ 30.
  • No significant diseases or clinically significant findings in a physical - examination.
  • No clinically significant abnormal laboratory values.
  • No clinically significant findings in the 12-lead electrocardiogram (ECG).
  • No clinically significant findings from the vital signs measurement.
  • Be informed of the nature of the study and given written consent prior to receiving any study procedure.

Negative for:

  • HIV.
  • Hepatitis B surface antigen and Hepatitis C antibody.
  • Urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
  • Urine cotinine test.
  • Serum HCG consistent with pregnancy (females only).

Females who participate in this study are:

  • unable to have children (e.g. post-menopausal, tubal ligation, hysterectomy) OR
  • willing to remain abstinent [not engage in sexual intercourse] OR
  • willing to use an effective method of double-barrier birth control [partner using condom and female using diaphragm, contraceptive sponge, spermicide or IUD]
  • Females who participate in this study are not pregnant and/or non-lactating.

Exclusion Criteria:

  • Known history or presence of any clinically significant medical condition.
  • Known or suspected carcinoma.
  • On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
  • Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
  • Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation).
  • Females taking oral or transdermal hormonal contraceptives within 14 days preceding period 1 dosing OR females having taken implanted or injected hormonal contraceptives within 6 months prior to period 1 dosing.
  • Requirement of any non-topical medication (prescription and/or over-the-counter) on a routine basis.
  • Difficulty fasting or consuming the standard meals.
  • Do not tolerate venipuncture.
  • Unable to read or sign the ICF.

Known history or presence of:

  • Hypersensitivity or idiosyncratic reaction to granisetron hydrochloride and/or any other drug substances with similar activity.
  • Alcoholism within the last 12 months.
  • Drug dependence and/or substance abuse.
  • Use of tobacco or nicotine-containing products, within the last 6 months.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00834522
2005-1021
No
Not Provided
Teva Pharmaceuticals USA
Not Provided
Principal Investigator: Xueyu (Eric) Chen, M.D., Ph. D. Pharma Medica
Teva Pharmaceuticals USA
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP